No CrossRef data available.
Article contents
El papel de la dopamina en los pacientes no deprimidos con antecedentes de intento de suicidio
Published online by Cambridge University Press: 12 May 2020
Resumen
Se dispone de varios datos sobre la implicación del sistema dopaminérgico en el control de la agresión dirigida hacia dentro. Propusimos anteriormente una implicación de la función dopaminér- gica D2 en la expresión de la conducta suicida demostrando una respuesta más pequeña de la hormona del crecimiento (HC) a la apomorfina, un agonista dopaminérgico, en pacientes deprimidos con antecedentes de intento de suicidio en comparación con pacientes que no habían intentado suicidarse. Para someter a prueba esta hipótesis, se midieron en el presente estudio las respuestas de la HC a la apo- morfina intravenosa en pacientes no deprimidos con antecedentes de intento de suicidio. El estudio se realizó en 17 pacientes varones no deprimidos con una puntuación inferior a 12 en la HAMD de 17 elementos. Se subagrupó a los pacientes según hubieran intentado suicidarse (N = 7) o no (N = 10). Las respuestas pico medias de la HC a la apomorfina difirieron significativamente entre los pacientes que habían intentado suicidarse y los que no: (media ± DT) para el pico de HC, 10,4 ± 8,2 ng/mL frente a 27,3 ± 13,1 ng/ml, F = 9,0, P= 0,009. En conclusión, las perturbaciones dopaminérgicas parecen desempeñar un papel en la biología de la agresión dirigida hacia dentro en los pacientes no deprimidos.
- Type
- Comunicación Breve
- Information
- Copyright
- Copyright © European Psychiatric Association 2002
References
Bibliografía
Agren, H.Life at risk: markers of suicidality in depres-sion. Psychiat Dev 1983;1:87-104.Google Scholar
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. rev. Washington DC: APA; 1987.Google Scholar
Ansseau, MScheyvaerts, MDoumont, APoirrier, RLegros, JJFranck, G.Concurrent use of REM latency, dexamethasone suppression, clonidine and apomorphi-ne tests as biological markers of endogenous depres-sion. Psychiatry Res 1984;12:261-72.CrossRefGoogle Scholar
Arranz, BBlennow, KEriksson, AMansson, JEMarcusson, J.Serotonergic, noradrenergic, and dopami-nergic measures in suicide brains. Biol Psychiatry 1997;41:1000-9.CrossRefGoogle ScholarPubMed
Beskow, JGottfries, CRoos, BWinblad, B.Determination of monoamine and monoamine metabo-lites in the human brain: postmortem studies in a group of suicides and in a control group. Acta Psychiatr Scand 1976;53:7-20.CrossRefGoogle Scholar
Bowden, CCheetharn, SCLowther, SRatona, CLECrompton, MRHorton, RW.Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res 1997;769:135-40.CrossRefGoogle ScholarPubMed
Crow, TJCross, AJCooper, SJ, et al.Neurotransmitter receptors and monoamine metabolites in the brains of patients with alzheimer-type dementia and depression and suicides. Neuropsychopharmacology 1984;23:1561-9.Google ScholarPubMed
Engstrom, GAlling, CBlennow, KRegnéll, GTräskrnan-Bendz, L.Reduced cerebrospinal HVA concen-trations and HVA/ 5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 1999;9:399-405.CrossRefGoogle Scholar
Franchimont, P.Le dosage radioimmunologique de l’hormone de croissance humaine. Cah Med Lyon 1968;44:887-98.Google Scholar
Hamilton, M.A rating scale for depression. J Neurol Neurosurg Psychiat 1960;23:56-62.CrossRefGoogle ScholarPubMed
Laakmann, G.Psychopharmacology and depression research. Berlin: Springer-Verlag; 1990.CrossRefGoogle Scholar
Mann, JJMalone, KM.Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry 1997;41:162-71.CrossRefGoogle ScholarPubMed
Montgomery, SAMontgomery, D.Pharmacological pre-vention of suicidal behavior. J Affective Disord 1982;4:291-8.CrossRefGoogle Scholar
Ohmori, TArara, RCMeltzer, HY.Serotonergic measures in suicide brain: the concentration of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims. Biol Psychiatry 1992;32:57-71.CrossRefGoogle ScholarPubMed
Pitchot, W. HansenneGonzalez Moreno, AAnsseau, M.Suicidal behavior and growth hormona response to apomorphine test. Biol Psychiatry 1992;31:1213-9.CrossRefGoogle Scholar
Pitchot, WGonzalez Moreno, AHansenne, MAnsseau, M.Growth hormona response to clonidine in nonde-pressed patients with a history of suicide attempts. Biol Psychiatry 1995;37:201-3.CrossRefGoogle Scholar
Pitchot, WHansenne, MGonzalez Moreno, AAnsseau, M.Effect of previous antidepressant therapy on the growth hormone response to apomorphine. Neuropsychobiology 1995b;32:19-22.CrossRefGoogle Scholar
Pitchot, WReggers, JPinto, EHansenne Fuchs, SPirard, S, et al.Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinology 2001;26:331-3.CrossRefGoogle ScholarPubMed
Roy, AAgren, Al’ickar, DLinnoila, MDoran, ACutler, N, et al.Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindolacetic acid ratios in depressed patients: Relationship to suicidal behavior and dexamethasone nonsuppression. Am J Psychiatry 1986;143:1539-45.Google Scholar
Roy, ADe Jong, JLinnoila, M.Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a 5-years follow-up study. Arch Gen Psychiatry 1989;46:609-12.CrossRefGoogle Scholar
Roy, AKaroum, FPollack, S.Marked reduction in inde-xes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 1992;49:447-50.CrossRefGoogle ScholarPubMed
Roy, APollack, S.Are cerebrospinal fluid or urinary monoamine metabolite measures stronger correlates of suicidal behavior in depression? Neuropsychobiology 1994;29:164-7.CrossRefGoogle ScholarPubMed
Traskman, LAsberg, MBertilsson, LSjostrand, L.Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981;38:631-9.CrossRefGoogle ScholarPubMed
Träskrnan-Bendz, LAlling, CAlsén, MRegnéll, GSimonsson, POhman, R.The role of monoamines in suicidal behavior. Acta Psychiatr Scand 1993;371(Suppl):45-7.CrossRefGoogle Scholar